Selected research
Market Structure
Global Non Corticosteroid Anti-inflammatory Eyedrops Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Non Corticosteroid Anti-inflammatory Eyedrops market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Non Corticosteroid Anti-inflammatory Eyedrops is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Non Corticosteroid Anti-inflammatory Eyedrops is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Non Corticosteroid Anti-inflammatory Eyedrops is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Non Corticosteroid Anti-inflammatory Eyedrops is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Non Corticosteroid Anti-inflammatory Eyedrops include Novartis AG, Allergan, Inc., Walgreens, Viva Opti-Free, Visine, Systane, Staples, Similasan Corporation and Rite Aid, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Non Corticosteroid Anti-inflammatory Eyedrops market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Non Corticosteroid Anti-inflammatory Eyedrops and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Non Corticosteroid Anti-inflammatory Eyedrops sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non Corticosteroid Anti-inflammatory Eyedrops market size, projected growth trends, production technologies, key applications, and end-use industries.
Non Corticosteroid Anti-inflammatory Eyedrops Segment by Company
Novartis AG
Allergan, Inc.
Walgreens
Viva Opti-Free
Visine
Systane
Staples
Similasan Corporation
Rite Aid
Meda Pharmaceuticals Inc
Clear eyes
Cigna
Bausch & Lomb Inc
Bausch & Lomb
Alcon
Non Corticosteroid Anti-inflammatory Eyedrops Segment by Type
Diclofenac
Mugabe
Ocufen
Others
Non Corticosteroid Anti-inflammatory Eyedrops Segment by Application
Adult
Children
Non Corticosteroid Anti-inflammatory Eyedrops Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non Corticosteroid Anti-inflammatory Eyedrops market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non Corticosteroid Anti-inflammatory Eyedrops and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non Corticosteroid Anti-inflammatory Eyedrops.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Non Corticosteroid Anti-inflammatory Eyedrops market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non Corticosteroid Anti-inflammatory Eyedrops manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non Corticosteroid Anti-inflammatory Eyedrops in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Non Corticosteroid Anti-inflammatory Eyedrops in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Non Corticosteroid Anti-inflammatory Eyedrops Industry Trends
Table 2. Non Corticosteroid Anti-inflammatory Eyedrops Industry Drivers
Table 3. Non Corticosteroid Anti-inflammatory Eyedrops Industry Opportunities and Challenges
Table 4. Non Corticosteroid Anti-inflammatory Eyedrops Industry Restraints
Table 5. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Manufacturers (W Units) & (2021-2026)
Table 8. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Manufacturers
Table 9. Global Non Corticosteroid Anti-inflammatory Eyedrops Average Sales Price (US$/Unit) of Manufacturers (2021-2026)
Table 10. Global Non Corticosteroid Anti-inflammatory Eyedrops Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Non Corticosteroid Anti-inflammatory Eyedrops Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Non Corticosteroid Anti-inflammatory Eyedrops Manufacturers, Product Type & Application
Table 13. Global Non Corticosteroid Anti-inflammatory Eyedrops Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Non Corticosteroid Anti-inflammatory Eyedrops by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Diclofenac
Table 17. Major Manufacturers of Mugabe
Table 18. Major Manufacturers of Ocufen
Table 19. Major Manufacturers of Others
Table 20. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type 2021 VS 2025 VS 2032 (W Units)
Table 21. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type (2021-2026) & (W Units)
Table 22. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type (2027-2032) & (W Units)
Table 23. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Type (2021-2026)
Table 24. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Type (2027-2032)
Table 25. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Type 2021 VS 2025 VS 2032 (W Units)
Table 26. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Type (2021-2026) & (W Units)
Table 27. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Type (2027-2032) & (W Units)
Table 28. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Type (2021-2026)
Table 29. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Type (2027-2032)
Table 30. Major Manufacturers of Adult
Table 31. Major Manufacturers of Children
Table 32. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application 2021 VS 2025 VS 2032 (W Units)
Table 33. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application (2021-2026) & (W Units)
Table 34. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application (2027-2032) & (W Units)
Table 35. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Application (2021-2026)
Table 36. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Application (2027-2032)
Table 37. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Application 2021 VS 2025 VS 2032 (W Units)
Table 38. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Application (2021-2026) & (W Units)
Table 39. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Application (2027-2032) & (W Units)
Table 40. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Application (2021-2026)
Table 41. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Application (2027-2032)
Table 42. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Region: 2021 VS 2025 VS 2032 (W Units)
Table 43. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Region (2021-2026) & (W Units)
Table 44. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Region (2021-2026)
Table 45. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Forecasted by Region (2027-2032) & (W Units)
Table 46. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Forecasted Market Share by Region (2027-2032)
Table 47. North America Non Corticosteroid Anti-inflammatory Eyedrops Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units)
Table 48. North America Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2026) & (W Units)
Table 49. North America Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2027-2032) & (W Units)
Table 50. Europe Non Corticosteroid Anti-inflammatory Eyedrops Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units)
Table 51. Europe Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2026) & (W Units)
Table 52. Europe Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2027-2032) & (W Units)
Table 53. Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units)
Table 54. Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2026) & (W Units)
Table 55. Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2027-2032) & (W Units)
Table 56. South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units)
Table 57. South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2026) & (W Units)
Table 58. South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2027-2032) & (W Units)
Table 59. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 60. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region (2021-2026) & (US$ Million)
Table 61. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region (2027-2032) & (US$ Million)
Table 62. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Region (2021-2026)
Table 63. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Region (2027-2032)
Table 64. Novartis AG Company Information
Table 65. Novartis AG Business Overview
Table 66. Novartis AG Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 67. Novartis AG Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 68. Novartis AG Recent Development
Table 69. Allergan, Inc. Company Information
Table 70. Allergan, Inc. Business Overview
Table 71. Allergan, Inc. Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 72. Allergan, Inc. Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 73. Allergan, Inc. Recent Development
Table 74. Walgreens Company Information
Table 75. Walgreens Business Overview
Table 76. Walgreens Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 77. Walgreens Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 78. Walgreens Recent Development
Table 79. Viva Opti-Free Company Information
Table 80. Viva Opti-Free Business Overview
Table 81. Viva Opti-Free Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 82. Viva Opti-Free Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 83. Viva Opti-Free Recent Development
Table 84. Visine Company Information
Table 85. Visine Business Overview
Table 86. Visine Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 87. Visine Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 88. Visine Recent Development
Table 89. Systane Company Information
Table 90. Systane Business Overview
Table 91. Systane Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 92. Systane Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 93. Systane Recent Development
Table 94. Staples Company Information
Table 95. Staples Business Overview
Table 96. Staples Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 97. Staples Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 98. Staples Recent Development
Table 99. Similasan Corporation Company Information
Table 100. Similasan Corporation Business Overview
Table 101. Similasan Corporation Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 102. Similasan Corporation Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 103. Similasan Corporation Recent Development
Table 104. Rite Aid Company Information
Table 105. Rite Aid Business Overview
Table 106. Rite Aid Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 107. Rite Aid Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 108. Rite Aid Recent Development
Table 109. Meda Pharmaceuticals Inc Company Information
Table 110. Meda Pharmaceuticals Inc Business Overview
Table 111. Meda Pharmaceuticals Inc Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 112. Meda Pharmaceuticals Inc Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 113. Meda Pharmaceuticals Inc Recent Development
Table 114. Clear eyes Company Information
Table 115. Clear eyes Business Overview
Table 116. Clear eyes Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 117. Clear eyes Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 118. Clear eyes Recent Development
Table 119. Cigna Company Information
Table 120. Cigna Business Overview
Table 121. Cigna Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 122. Cigna Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 123. Cigna Recent Development
Table 124. Bausch & Lomb Inc Company Information
Table 125. Bausch & Lomb Inc Business Overview
Table 126. Bausch & Lomb Inc Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 127. Bausch & Lomb Inc Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 128. Bausch & Lomb Inc Recent Development
Table 129. Bausch & Lomb Company Information
Table 130. Bausch & Lomb Business Overview
Table 131. Bausch & Lomb Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 132. Bausch & Lomb Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 133. Bausch & Lomb Recent Development
Table 134. Alcon Company Information
Table 135. Alcon Business Overview
Table 136. Alcon Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 137. Alcon Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
Table 138. Alcon Recent Development
Table 139. Key Raw Materials
Table 140. Raw Materials Key Suppliers
Table 141. Non Corticosteroid Anti-inflammatory Eyedrops Distributors List
Table 142. Non Corticosteroid Anti-inflammatory Eyedrops Customers List
Table 143. Research Programs/Design for This Report
Table 144. Authors List of This Report
Table 145. Secondary Sources
Table 146. Primary Sources
List of Figures
Figure 1. Non Corticosteroid Anti-inflammatory Eyedrops Product Image
Figure 2. Global Non Corticosteroid Anti-inflammatory Eyedrops Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Non Corticosteroid Anti-inflammatory Eyedrops Market Size (2021-2032) & (US$ Million)
Figure 4. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales (2021-2032) & (W Units)
Figure 5. Global Non Corticosteroid Anti-inflammatory Eyedrops Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Non Corticosteroid Anti-inflammatory Eyedrops Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Diclofenac Image
Figure 9. Mugabe Image
Figure 10. Ocufen Image
Figure 11. Others Image
Figure 12. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type (2021 VS 2025 VS 2032) & (W Units)
Figure 13. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share 2021 VS 2025 VS 2032
Figure 14. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Type (2021-2032)
Figure 15. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Type (2021 VS 2025 VS 2032) & (W Units)
Figure 16. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share 2021 VS 2025 VS 2032
Figure 17. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Type (2021-2032)
Figure 18. Adult Image
Figure 19. Children Image
Figure 20. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application (2021 VS 2025 VS 2032) & (W Units)
Figure 21. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share 2021 VS 2025 VS 2032
Figure 22. Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Application (2021-2032)
Figure 23. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Application (2021 VS 2025 VS 2032) & (W Units)
Figure 24. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share 2021 VS 2025 VS 2032
Figure 25. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Application (2021-2032)
Figure 26. North America Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 27. North America Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Country (2021-2032)
Figure 28. U.S. Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 29. Canada Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 30. Mexico Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 31. Europe Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 32. Europe Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Country (2021-2032)
Figure 33. Germany Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 34. France Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 35. U.K. Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 36. Italy Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 37. Netherlands Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 38. Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 39. Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Country (2021-2032)
Figure 40. China Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 41. Japan Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 42. South Korea Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 43. Southeast Asia Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 44. India Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 45. Australia Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 46. South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 47. South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Country (2021-2032)
Figure 48. Brazil Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 49. South Africa Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 50. Saudi Arabia Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 51. Turkey Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 52. Argentina Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 53. UAE Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 54. Egypt Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 55. Chile Non Corticosteroid Anti-inflammatory Eyedrops Sales and Growth Rate (2021-2032) & (W Units)
Figure 56. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 57. Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 58. North America Non Corticosteroid Anti-inflammatory Eyedrops Revenue (2021-2032) & (US$ Million)
Figure 59. North America Non Corticosteroid Anti-inflammatory Eyedrops Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 60. Europe Non Corticosteroid Anti-inflammatory Eyedrops Revenue (2021-2032) & (US$ Million)
Figure 61. Europe Non Corticosteroid Anti-inflammatory Eyedrops Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 62. Asia-Pacific Non Corticosteroid Anti-inflammatory Eyedrops Revenue (2021-2032) & (US$ Million)
Figure 63. Asia-Pacific Non Corticosteroid Anti-inflammatory Eyedrops Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 64. South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Revenue (2021-2032) & (US$ Million)
Figure 65. South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 66. Non Corticosteroid Anti-inflammatory Eyedrops Value Chain
Figure 67. Manufacturing Cost Structure
Figure 68. Non Corticosteroid Anti-inflammatory Eyedrops Production Mode & Process
Figure 69. Direct Comparison with Distribution Share
Figure 70. Distributors Profiles
Figure 71. Years Considered
Figure 72. Research Process
Figure 73. Key Executives Interviewed
Scope & coverage.
Types
- Diclofenac
- Mugabe
- Ocufen
- Others
Applications
- Adult
- Children
Companies covered
- Novartis AG
- Allergan, Inc.
- Walgreens
- Viva Opti-Free
- Visine
- Systane
- Staples
- Similasan Corporation
- Rite Aid
- Meda Pharmaceuticals Inc
- Clear eyes
- Cigna
- Bausch & Lomb Inc
- Bausch & Lomb
- Alcon
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Non Corticosteroid Anti-inflammatory Eyedrops Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Non Corticosteroid Anti-inflammatory Eyedrops Market Dynamics
- 2.1 Non Corticosteroid Anti-inflammatory Eyedrops Industry Trends
- 2.2 Non Corticosteroid Anti-inflammatory Eyedrops Industry Drivers
- 2.3 Non Corticosteroid Anti-inflammatory Eyedrops Industry Opportunities and Challenges
- 2.4 Non Corticosteroid Anti-inflammatory Eyedrops Industry Restraints
3 Non Corticosteroid Anti-inflammatory Eyedrops Market by Manufacturers
- 3.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Manufacturers (2021-2026)
- 3.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Manufacturers (2021-2026)
- 3.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Non Corticosteroid Anti-inflammatory Eyedrops Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Non Corticosteroid Anti-inflammatory Eyedrops Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Non Corticosteroid Anti-inflammatory Eyedrops Manufacturers, Product Type & Application
- 3.7 Global Non Corticosteroid Anti-inflammatory Eyedrops Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Non Corticosteroid Anti-inflammatory Eyedrops Players Market Share by Revenue in 2025
- 3.8.3 2025 Non Corticosteroid Anti-inflammatory Eyedrops Tier 1, Tier 2, and Tier 3
4 Non Corticosteroid Anti-inflammatory Eyedrops Market by Type
- 4.1 Non Corticosteroid Anti-inflammatory Eyedrops Type Introduction
- 4.1.1 Diclofenac
- 4.1.2 Mugabe
- 4.1.3 Ocufen
- 4.1.4 Others
- 4.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type
- 4.2.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type (2021-2032)
- 4.2.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Type (2021-2032)
- 4.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Type
- 4.3.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Type (2021-2032)
- 4.3.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Type (2021-2032)
5 Non Corticosteroid Anti-inflammatory Eyedrops Market by Application
- 5.1 Non Corticosteroid Anti-inflammatory Eyedrops Application Introduction
- 5.1.1 Adult
- 5.1.2 Children
- 5.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application
- 5.2.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application (2021-2032)
- 5.2.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Application (2021-2032)
- 5.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Application
- 5.3.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Application (2021-2032)
- 5.3.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Application (2021-2032)
6 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Region
- 6.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Region (2021-2032)
- 6.2.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Region (2021-2026)
- 6.2.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Non Corticosteroid Anti-inflammatory Eyedrops Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Non Corticosteroid Anti-inflammatory Eyedrops Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region
- 7.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region
- 7.1.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region (2021-2026)
- 7.1.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region (2027-2032)
- 7.1.4 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Non Corticosteroid Anti-inflammatory Eyedrops Revenue (2021-2032)
- 7.2.2 North America Non Corticosteroid Anti-inflammatory Eyedrops Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Non Corticosteroid Anti-inflammatory Eyedrops Revenue (2021-2032)
- 7.3.2 Europe Non Corticosteroid Anti-inflammatory Eyedrops Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Non Corticosteroid Anti-inflammatory Eyedrops Revenue (2021-2032)
- 7.4.2 Asia-Pacific Non Corticosteroid Anti-inflammatory Eyedrops Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novartis AG
- 8.1.1 Novartis AG Company Information
- 8.1.2 Novartis AG Business Overview
- 8.1.3 Novartis AG Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novartis AG Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.1.5 Novartis AG Recent Developments
- 8.2 Allergan, Inc.
- 8.2.1 Allergan, Inc. Company Information
- 8.2.2 Allergan, Inc. Business Overview
- 8.2.3 Allergan, Inc. Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Allergan, Inc. Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.2.5 Allergan, Inc. Recent Developments
- 8.3 Walgreens
- 8.3.1 Walgreens Company Information
- 8.3.2 Walgreens Business Overview
- 8.3.3 Walgreens Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Walgreens Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.3.5 Walgreens Recent Developments
- 8.4 Viva Opti-Free
- 8.4.1 Viva Opti-Free Company Information
- 8.4.2 Viva Opti-Free Business Overview
- 8.4.3 Viva Opti-Free Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Viva Opti-Free Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.4.5 Viva Opti-Free Recent Developments
- 8.5 Visine
- 8.5.1 Visine Company Information
- 8.5.2 Visine Business Overview
- 8.5.3 Visine Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Visine Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.5.5 Visine Recent Developments
- 8.6 Systane
- 8.6.1 Systane Company Information
- 8.6.2 Systane Business Overview
- 8.6.3 Systane Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Systane Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.6.5 Systane Recent Developments
- 8.7 Staples
- 8.7.1 Staples Company Information
- 8.7.2 Staples Business Overview
- 8.7.3 Staples Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Staples Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.7.5 Staples Recent Developments
- 8.8 Similasan Corporation
- 8.8.1 Similasan Corporation Company Information
- 8.8.2 Similasan Corporation Business Overview
- 8.8.3 Similasan Corporation Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Similasan Corporation Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.8.5 Similasan Corporation Recent Developments
- 8.9 Rite Aid
- 8.9.1 Rite Aid Company Information
- 8.9.2 Rite Aid Business Overview
- 8.9.3 Rite Aid Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Rite Aid Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.9.5 Rite Aid Recent Developments
- 8.10 Meda Pharmaceuticals Inc
- 8.10.1 Meda Pharmaceuticals Inc Company Information
- 8.10.2 Meda Pharmaceuticals Inc Business Overview
- 8.10.3 Meda Pharmaceuticals Inc Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Meda Pharmaceuticals Inc Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.10.5 Meda Pharmaceuticals Inc Recent Developments
- 8.11 Clear eyes
- 8.11.1 Clear eyes Company Information
- 8.11.2 Clear eyes Business Overview
- 8.11.3 Clear eyes Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Clear eyes Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.11.5 Clear eyes Recent Developments
- 8.12 Cigna
- 8.12.1 Cigna Company Information
- 8.12.2 Cigna Business Overview
- 8.12.3 Cigna Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Cigna Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.12.5 Cigna Recent Developments
- 8.13 Bausch & Lomb Inc
- 8.13.1 Bausch & Lomb Inc Company Information
- 8.13.2 Bausch & Lomb Inc Business Overview
- 8.13.3 Bausch & Lomb Inc Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Bausch & Lomb Inc Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.13.5 Bausch & Lomb Inc Recent Developments
- 8.14 Bausch & Lomb
- 8.14.1 Bausch & Lomb Company Information
- 8.14.2 Bausch & Lomb Business Overview
- 8.14.3 Bausch & Lomb Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Bausch & Lomb Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.14.5 Bausch & Lomb Recent Developments
- 8.15 Alcon
- 8.15.1 Alcon Company Information
- 8.15.2 Alcon Business Overview
- 8.15.3 Alcon Non Corticosteroid Anti-inflammatory Eyedrops Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Alcon Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 8.15.5 Alcon Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Non Corticosteroid Anti-inflammatory Eyedrops Value Chain Analysis
- 9.1.1 Non Corticosteroid Anti-inflammatory Eyedrops Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Non Corticosteroid Anti-inflammatory Eyedrops Production Mode & Process
- 9.2 Non Corticosteroid Anti-inflammatory Eyedrops Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Non Corticosteroid Anti-inflammatory Eyedrops Distributors
- 9.2.3 Non Corticosteroid Anti-inflammatory Eyedrops Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst